{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:15:57Z","timestamp":1790619357780,"version":"4.1.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,12,1]]},"abstract":"<jats:p>The development of multiple myeloma (MM) bone disease is mediated by increased number and activity of osteoclasts (OCs). Using an in vitro osteoclastogenesis model consisting of unstimulated and unfractionated peripheral blood mononuclear cells (PBMCs) from patients with MM, we showed that T cells support the formation of OCs with longer survival. Different from T-cell\u2013depleted MM PBMC cultures, exogenous macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor-\u03baB ligand (RANKL) were necessary for the formation of OCs; however, they did not exhibit longer survival. We found up-regulated production of RANKL, osteoprotegerin (OPG), and TNF-related apoptosis-inducing ligand (TRAIL) by fresh MM T cells. Despite high OPG levels, the persistence of osteoclastogenesis can be related to the formation of the OPG\/TRAIL complex demonstrated by immunoprecipitation experiments and the addition of anti-TRAIL antibody which decreases OC formation. OCs overexpressed TRAIL decoy receptor DcR2 in the presence of MM T cells and death receptor DR4 in T-cell\u2013depleted cultures. In addition, increased Bcl-2\/Bax (B-cell lymphoma-2\/Bcl2-associated protein X) ratio, following Bcl-2 up-regulation, was detected in OCs generated in the presence of T cells. Our results highlight that MM T cells support OC formation and survival, possibly involving OPG\/TRAIL interaction and unbalanced OC expression of TRAIL death and decoy receptors.<\/jats:p>","DOI":"10.1182\/blood-2004-02-0474","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T00:24:05Z","timestamp":1092356645000},"page":"3722-3730","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":122,"title":["T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG\/TRAIL interaction"],"prefix":"10.1182","volume":"104","author":[{"given":"Silvia","family":"Colucci","sequence":"first","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomina","family":"Brunetti","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Rizzi","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Zonno","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Mori","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziana","family":"Colaianni","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Del Prete","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Faccio","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Liso","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Capalbo","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Liso","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Zallone","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Grano","sequence":"additional","affiliation":[{"name":"From the Department of Human Anatomy and Histology, Hematology Section, University of Bari Medical School, Bari, Italy; the Department of Internal Medicine and Public Medicine, University of Bari Medical School, Bari, Italy; and Hematology Section, University of Foggia Medical School, Foggia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218344129200_REF1","doi-asserted-by":"crossref","unstructured":"Barille\u0301-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma. 2003;44: 1463-1467.","DOI":"10.3109\/10428190309178765"},{"key":"2020021218344129200_REF2","doi-asserted-by":"crossref","unstructured":"Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma. Hematol J. 2003;4: 310-314.","DOI":"10.1038\/sj.thj.6200313"},{"key":"2020021218344129200_REF3","doi-asserted-by":"crossref","unstructured":"Tian E, Zhan F, Walker R, et al. The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349: 2483-2494.","DOI":"10.1056\/NEJMoa030847"},{"key":"2020021218344129200_REF4","doi-asserted-by":"crossref","unstructured":"Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397: 315-323.","DOI":"10.1038\/16852"},{"key":"2020021218344129200_REF5","doi-asserted-by":"crossref","unstructured":"Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402: 304-309.","DOI":"10.1038\/46303"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Takayanagi H, Ogasawara K, Hida S, et al. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000;408: 600-605.","DOI":"10.1038\/35046102"},{"key":"2020021218344129200_REF7","doi-asserted-by":"crossref","unstructured":"Choi Y, Woo KM, Ko SH, et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol. 2001;31: 2179-2188.","DOI":"10.1002\/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Weitzmann MN, Cenci S, Rifas L, Haug J, Dispersio J, Pacifici R. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res. 2001;6: 328-337.","DOI":"10.1359\/jbmr.2001.16.2.328"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Takayanagi H, Kim S, Taniguchi T. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 2002;4: 227-232.","DOI":"10.1186\/ar581"},{"key":"2020021218344129200_REF10","doi-asserted-by":"crossref","unstructured":"Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002;99: 634-640.","DOI":"10.1182\/blood.V99.2.634"},{"key":"2020021218344129200_REF11","doi-asserted-by":"crossref","unstructured":"Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 2002;100: 4615-4621.","DOI":"10.1182\/blood-2002-04-1121"},{"key":"2020021218344129200_REF12","doi-asserted-by":"crossref","unstructured":"Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423: 337-342.","DOI":"10.1038\/nature01658"},{"key":"2020021218344129200_REF13","doi-asserted-by":"crossref","unstructured":"Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A. 1998;95: 3597-3602.","DOI":"10.1073\/pnas.95.7.3597"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165-176.","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"2020021218344129200_REF15","doi-asserted-by":"crossref","unstructured":"Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem. 1999;274: 13613-13618.","DOI":"10.1074\/jbc.274.19.13613"},{"key":"2020021218344129200_REF16","doi-asserted-by":"crossref","unstructured":"Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer. 2001;92: 460-470.","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D"},{"key":"2020021218344129200_REF17","doi-asserted-by":"crossref","unstructured":"Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cell, bone loss, and mammalian evolution. Ann Rev Immunol. 2002;20: 795-823.","DOI":"10.1146\/annurev.immunol.20.100301.064753"},{"key":"2020021218344129200_REF18","doi-asserted-by":"crossref","unstructured":"Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kB (RANKL) receptors. J Exp Med. 1999;190: 1741-1754.","DOI":"10.1084\/jem.190.12.1741"},{"key":"2020021218344129200_REF19","doi-asserted-by":"crossref","unstructured":"Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNF\u03b1 potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002;143: 1108-1118.","DOI":"10.1210\/endo.143.3.8701"},{"key":"2020021218344129200_REF20","doi-asserted-by":"crossref","unstructured":"Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390: 175-179.","DOI":"10.1038\/36593"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272: 25190-25194.","DOI":"10.1074\/jbc.272.40.25190"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89: 309-319.","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999;96: 3540-3545.","DOI":"10.1073\/pnas.96.7.3540"},{"key":"2020021218344129200_REF24","doi-asserted-by":"crossref","unstructured":"Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000;97: 1566-1571.","DOI":"10.1073\/pnas.97.4.1566"},{"key":"2020021218344129200_REF25","doi-asserted-by":"crossref","unstructured":"Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273: 14363-14367.","DOI":"10.1074\/jbc.273.23.14363"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276: 111-113.","DOI":"10.1126\/science.276.5309.111"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277: 815-818.","DOI":"10.1126\/science.277.5327.815"},{"key":"2020021218344129200_REF28","doi-asserted-by":"crossref","unstructured":"Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277: 818-821.","DOI":"10.1126\/science.277.5327.818"},{"key":"2020021218344129200_REF29","doi-asserted-by":"crossref","unstructured":"Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L\/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood. 2001;98: 2183-2192.","DOI":"10.1182\/blood.V98.7.2183"},{"key":"2020021218344129200_REF30","doi-asserted-by":"crossref","unstructured":"Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74: 609-619.","DOI":"10.1016\/0092-8674(93)90509-O"},{"key":"2020021218344129200_REF31","doi-asserted-by":"crossref","unstructured":"Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281: 1322-1326.","DOI":"10.1126\/science.281.5381.1322"},{"key":"2020021218344129200_REF32","unstructured":"Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin is a survival factor for human prostate cancer cell. Cancer Res. 2002;62: 1619-1623."},{"key":"2020021218344129200_REF33","unstructured":"Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003;63: 912-916."},{"key":"2020021218344129200_REF34","doi-asserted-by":"crossref","unstructured":"Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98: 11581-11586.","DOI":"10.1073\/pnas.201394498"},{"key":"2020021218344129200_REF35","doi-asserted-by":"crossref","unstructured":"Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98: 3527-3533.","DOI":"10.1182\/blood.V98.13.3527"},{"key":"2020021218344129200_REF36","doi-asserted-by":"crossref","unstructured":"Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36: 842-854.","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"2020021218344129200_REF37","unstructured":"Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Hoffbrand AV, Brain MC, Jirsh J, eds. Recent Advances in Hematology. New York, NY: Churchill Livingstone; 1977: 243-261."},{"key":"2020021218344129200_REF38","doi-asserted-by":"crossref","unstructured":"Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Nat Acad Sci U S A. 2001; 98: 13960-13965.","DOI":"10.1073\/pnas.251534698"},{"key":"2020021218344129200_REF39","doi-asserted-by":"crossref","unstructured":"Teng YT, Nguyen H, Gao X, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest. 2000;106: 59-67.","DOI":"10.1172\/JCI10763"},{"key":"2020021218344129200_REF40","doi-asserted-by":"crossref","unstructured":"Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44: 1003-1012.","DOI":"10.1002\/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#"},{"key":"2020021218344129200_REF41","doi-asserted-by":"crossref","unstructured":"Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulation osteoprotegerin\/osteoclastogenesis inhibitory factor: increase serum concentrations in postmenopausal women with osteoporosis. J Bone Min Res. 1999; 14: 518-527.","DOI":"10.1359\/jbmr.1999.14.4.518"},{"key":"2020021218344129200_REF42","doi-asserted-by":"crossref","unstructured":"Feuerhem AJ, Borset M, Seidel C, et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol. 2001;30: 229-234.","DOI":"10.1080\/030097401316909585"},{"key":"2020021218344129200_REF43","doi-asserted-by":"crossref","unstructured":"Seidel C, Hjertner O, Abildgaard N, et al. Nordic Myeloma Study Group. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood. 2001;98: 2269-2271.","DOI":"10.1182\/blood.V98.7.2269"},{"key":"2020021218344129200_REF44","doi-asserted-by":"crossref","unstructured":"Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002;100: 3002-3007.","DOI":"10.1182\/blood-2002-04-1190"},{"key":"2020021218344129200_REF45","doi-asserted-by":"crossref","unstructured":"Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 2003;101: 2094-2098.","DOI":"10.1182\/blood-2002-09-2684"},{"key":"2020021218344129200_REF46","doi-asserted-by":"crossref","unstructured":"Martin-Villalba A, Herr I, Jeremias I, et al. CD95 ligand (Fas-L\/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci. 1999;19: 3809-3817.","DOI":"10.1523\/JNEUROSCI.19-10-03809.1999"},{"key":"2020021218344129200_","doi-asserted-by":"crossref","unstructured":"Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000;6: 564-567.","DOI":"10.1038\/75045"},{"key":"2020021218344129200_REF48","doi-asserted-by":"crossref","unstructured":"Simon AK, Williams O, Mongkolsapaya J, et al. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci U S A. 2001;98: 5158-5163.","DOI":"10.1073\/pnas.091100398"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/12\/3722\/1703905\/zh802304003722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/12\/3722\/1703905\/zh802304003722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:49:44Z","timestamp":1585871384000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/12\/3722\/89075\/T-cells-support-osteoclastogenesis-in-an-in-vitro"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,1]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-02-0474","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,1]]}}}